Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of Moderate Buy from Analysts

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price […]

Related Keywords

United States ,Jamesm Daly ,Richards Levy ,Piper Sandler ,Institutional Trading Of Madrigal Pharmaceuticals ,Global Retirement Partners ,News Ratings For Madrigal Pharmaceuticals Daily ,Cerity Partners ,Securities Exchange Commission ,Columbus Asset Advisors ,Madrigal Pharmaceuticals Inc ,Madrigal Pharmaceuticals Company Profile ,Madrigal Pharmaceuticals Trading ,Canaccord Genuity Group ,Analyst Recommendations For Madrigal Pharmaceuticals ,Nasdaq ,Osaic Holdings Inc ,Madrigal Pharmaceuticals ,Get Free Report ,Director James ,Exchange Commission ,Director Richard ,Retirement Partners ,Get Free ,Madrigal Pharmaceuticals Daily ,Nasdaq Mdgl ,Mdgl ,Medical ,87162t20 ,Ratings ,Consensus ,